Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Director · Chair and CEO | July 23, 2026 | July 24, 2026 |
| NewAmsterdam Pharma Co N.V.NAMS · Entity 1826 | Director | January 07, 2026 | January 10, 2026 |
| uniQure N.V.QURE · Entity 4162 | Director | January 27, 2017 | January 31, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date July 23, 2026 · Filed July 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 259,058 |
Ending reported balance
After 2026-07-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-07-23 · Exercise / conversion · Acquired 6,260 · Balance 265,318 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 2 · 2026-07-23 · Exercise / conversion · Acquired 4,440 · Balance 269,758 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-07-23 · Sale · Disposed 4,828 · Balance 264,930 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-07-23 · Sale · Disposed 5,872 · Balance 259,058 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.46 · Expires 2028-01-04 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-07-23 · Exercise / conversion · Disposed 6,260 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.16 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2026-07-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-07-23 · Exercise / conversion · Disposed 4,440 · Balance 0 F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy trust | 233,924 |
Reported balance
Holding disclosure · report date 2026-07-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 233,924 |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: This is the weighted average sales price representing 4,828 shares sold at prices ranging from $105.09 to $106.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F3: This is the weighted average sales price representing 5,872 shares sold at prices ranging from $106.09 to $106.78 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F4: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
NewAmsterdam Pharma Co N.V.
Report date January 07, 2026 · Filed January 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,360 |
Reported balance
After 2026-01-07 transaction · row 1
1 source rowRow 1 · 2026-01-07 · Grant · Acquired 3,400 · Balance 10,360 F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. F2: Each RSU was granted on January 7, 2026 for no consideration. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.45 · Expires 2036-01-07 | Direct | 15,300 |
Reported balance
After 2026-01-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-07 · Grant · Acquired 15,300 · Balance 15,300 F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
F2: Each RSU was granted on January 7, 2026 for no consideration.
F3: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
uniQure N.V.
Report date January 27, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.37 · Expires 2027-01-27 | Direct | 11,000 |
Reported balance
After 2017-01-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-27 · Grant · Acquired 11,000 · Balance 11,000 F1: The Stock Option vests 100% on January 27, 2018. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 16,000 |
Reported balance
After 2017-01-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-27 · Grant · Acquired 11,000 · Balance 16,000 F2: The Restricted Stock Unit vests 100% on January 27, 2018. F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests. |
Filing footnotes · ownership attribution and instrument terms
F1: The Stock Option vests 100% on January 27, 2018.
F2: The Restricted Stock Unit vests 100% on January 27, 2018.
F3: Expiration date is not applicable as the vested Restricted Stock Units shall be settled on the first business day following the date that such Restricted Stock Units vests.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2025 Filed Jul 15, 2025 21:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,492 | $102.66 | $461,148.72 |
DisclosureSEC source: 0001104506-25-000030 · wk-form4_1752616402.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,094 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,492 shares sold at prices ranging from $102.13 to $103.12 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:53 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,168 | $101.71 | $220,507.28 |
DisclosureSEC source: 0001104506-25-000030 · wk-form4_1752616402.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 238,586 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 2,168 shares sold at prices ranging from $101.10 to $102.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 15, 2025 Filed Jul 15, 2025 21:53 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001104506-25-000030 · wk-form4_1752616402.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:06 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001402051-25-000003 · wk-form4_1751486748.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 20,525 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 815 | $99.61 | $81,182.15 |
DisclosureSEC source: 0001402051-25-000003 · wk-form4_1751486748.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 815 shares sold at prices ranging from $99.40 to $100.26 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,349 | $98.83 | $232,151.67 |
DisclosureSEC source: 0001402051-25-000003 · wk-form4_1751486748.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,739 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 2,349 shares sold at prices ranging from $98.40 to $99.39 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:06 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,666 | $97.73 | $358,278.18 |
DisclosureSEC source: 0001402051-25-000003 · wk-form4_1751486748.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 237,088 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,666 shares sold at prices ranging from $97.40 to $98.38 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| July 01, 2025 Filed Jul 2, 2025 20:06 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001402051-25-000003 · wk-form4_1751486748.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 129,805 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 27,355 Underlying: Common Stock · 129,805 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 41,784 | $101.23 | $4,229,794.32 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F9 · price: This is the weighted average sales price representing 41,784 shares sold at prices ranging from $100.94 to $101.61 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 48,531 | $100.54 | $4,879,306.74 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 275,708 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · price: This is the weighted average sales price representing 48,531 shares sold at prices ranging from $99.94 to $100.93 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 32,490 | $99.51 | $3,233,079.90 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 324,239 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 32,490 shares sold at prices ranging from $98.94 to $99.93 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,000 | $98.50 | $689,500.00 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 356,729 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 7,000 shares sold at prices ranging from $97.93 to $98.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 129,805 | $10.85 | $1,408,384.25 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 363,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 904 | $101.39 | $91,656.56 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 303,554 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 904 shares sold at prices ranging from $101.20 to $101.58 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,300 | $100.70 | $231,610.00 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 304,458 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,300 shares sold at prices ranging from $100.19 to $101.07 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,558 | $99.65 | $155,254.70 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,758 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,558 shares sold at prices ranging from $99.17 to $100.16 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 16, 2025 Filed Jun 18, 2025 20:16 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 442 | $98.51 | $43,541.42 |
DisclosureSEC source: 0001628280-25-032117 · wk-form4_1750277810.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,316 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 442 shares sold at prices ranging from $98.08 to $98.94 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 03, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 5,472 | $71.50 | $391,248.00 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,758 F5 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 157,160 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,430 | $71.94 | $102,874.20 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,430 shares sold at prices ranging from $71.67 to $72.24 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,400 | $71.35 | $313,940.00 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 235,354 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,400 shares sold at prices ranging from $70.67 to $71.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,000 | $70.23 | $70,230.00 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 239,754 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,000 shares sold at prices ranging from $69.59 to $70.57 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:40 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-029368 · wk-form4_1749069612.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2024, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 163,990 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 1,716 | $68.54 | $117,614.64 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 1,716 shares sold at prices ranging from $68.50 to $68.59 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,251 | $68.13 | $153,360.63 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 235,640 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 2,251 shares sold at prices ranging from $67.49 to $68.47 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,863 | $66.90 | $191,534.70 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 237,891 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,863 shares sold at prices ranging from $66.42 to $67.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,088 | $68.49 | $485,457.12 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,230 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 7,088 shares sold at prices ranging from $68.38 to $68.59 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,480 | $67.96 | $304,460.80 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,318 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,480 shares sold at prices ranging from $67.38 to $68.37 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:18 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 9,489 | $66.87 | $634,529.43 |
DisclosureSEC source: 0001628280-25-027339 · wk-form4_1747948703.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 325,798 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 9,489 shares sold at prices ranging from $66.34 to $67.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:05 UTC | INSMED Inc INSM · Entity 3174 | GrantStock Option (right to buy) · Derivative | 108,380 | $0.00 Strike: $67.22 | $0.00 |
DisclosureSEC source: 0001628280-25-026583 · wk-form4_1747688749.xml · derivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,380 Underlying: Common Stock · 108,380 shares Expires 2035-05-15 F3 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:05 UTC | INSMED Inc INSM · Entity 3174 | GrantCommon Stock | 22,314 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-026583 · wk-form4_1747688749.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 335,287 F1 · shares: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2 · price: Each RSU was granted on May 15, 2025 for no consideration. Read SEC document |
| May 14, 2025 Filed May 15, 2025 20:33 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,771 | $65.61 | $247,415.31 |
DisclosureSEC source: 0001628280-25-025987 · wk-form4_1747341178.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 312,973 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:33 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 7,699 | $67.70 | $521,222.30 |
DisclosureSEC source: 0001628280-25-025987 · wk-form4_1747341178.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 316,744 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F3 · price: This is the weighted average sales price representing 7,699 shares sold at prices ranging from $67.11 to $67.81 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:33 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 9,743 | $66.40 | $646,935.20 |
DisclosureSEC source: 0001628280-25-025987 · wk-form4_1747341178.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 324,443 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F2 · price: This is the weighted average sales price representing 9,743 shares sold at prices ranging from $66.02 to $67.00 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:43 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-021897 · wk-form4_1746218581.xml · derivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 170,820 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:43 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 4,201 | $72.78 | $305,748.78 |
DisclosureSEC source: 0001628280-25-021897 · wk-form4_1746218581.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 4,201 shares sold at prices ranging from $72.59 to $73.10 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:43 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,629 | $72.24 | $189,918.96 |
DisclosureSEC source: 0001628280-25-021897 · wk-form4_1746218581.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 238,125 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 2,629 shares sold at prices ranging from $71.56 to $72.54 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:43 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-021897 · wk-form4_1746218581.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-017995 · wk-form4_1744834668.xml · derivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 177,650 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 600 | $71.30 | $42,780.00 |
DisclosureSEC source: 0001628280-25-017995 · wk-form4_1744834668.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 600 shares sold at prices ranging from $71.17 to $71.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,896 | $70.54 | $204,283.84 |
DisclosureSEC source: 0001628280-25-017995 · wk-form4_1744834668.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,524 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 2,896 shares sold at prices ranging from $70.12 to $71.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:17 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 3,334 | $69.62 | $232,113.08 |
DisclosureSEC source: 0001628280-25-017995 · wk-form4_1744834668.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 237,420 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,334 shares sold at prices ranging from $69.06 to $69.92 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:17 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 6,830 | $10.85 | $74,105.50 |
DisclosureSEC source: 0001628280-25-017995 · wk-form4_1744834668.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 240,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionStock Option (right to buy) · Derivative | 6,830 | $0.00 Strike: $10.85 | $0.00 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 184,480 Underlying: Common Stock · 6,830 shares Expires 2026-05-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. All options are currently exercisable. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 805 | $75.26 | $60,584.30 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 233,924 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 805 shares sold at prices ranging from $75.10 to $75.46 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 2,232 | $74.78 | $166,908.96 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 234,729 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 2,232 shares sold at prices ranging from $74.10 to $75.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:25 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 772 | $73.44 | $56,695.68 |
DisclosureSEC source: 0001628280-25-016508 · wk-form4_1743711913.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Indirect · By the Katie Procter Dynasty Trust Disclosed balance after: 236,961 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 772 shares sold at prices ranging from $73.04 to $73.77 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.